Ocular immunology and inflammation · 2025
Bilateral Anterior Segment Hyphema and Ocular Hypotony Following Treatment with Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto).
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Henry Roger K, Habiel Miriam, Zhu Aretha, Gejerman Glen, Khouri Albert S, Tsui Jonathan C
Аннотация
PURPOSE: We describe a case of severe bilateral anterior segment neovascularization leading to hyphema in a patient treated with Lutetium (177Lu) vipivotide tetraxetan for metastatic castration-resistant prostate cancer (mCRPC).
METHODS: Case report with multimodal imaging.
RESULTS: A 77-year-old patient was referred for evaluation of a two-day history of blurry vision. At presentation, the exam was significant for bilateral hyphema, elevated intraocular pressure, and significant microcystic edema. Gonioscopy revealed neovascularization of the anterior segment. Multimodal imaging revealed intraretinal hemorrhages without neovascular retinopathy, metastases, or carotid occlusive disease. The patient was treated medically, but developed significant hypotony necessitating postponement of therapy.
CONCLUSION: This case demonstrates a potential ocular adverse reaction to Lutetium (177Lu) vipivotide tetraxetan therapy.
METHODS: Case report with multimodal imaging.
RESULTS: A 77-year-old patient was referred for evaluation of a two-day history of blurry vision. At presentation, the exam was significant for bilateral hyphema, elevated intraocular pressure, and significant microcystic edema. Gonioscopy revealed neovascularization of the anterior segment. Multimodal imaging revealed intraretinal hemorrhages without neovascular retinopathy, metastases, or carotid occlusive disease. The patient was treated medically, but developed significant hypotony necessitating postponement of therapy.
CONCLUSION: This case demonstrates a potential ocular adverse reaction to Lutetium (177Lu) vipivotide tetraxetan therapy.